Brought to you by 
Torii gets Japanese marketing rights to HIV therapy from parent Japan Tobacco
Sep 2012
Executive Summary
Japan Tobacco Inc. has licensed its Japanese pharma subsidiary Torii Pharmaceutical Co. Ltd. exclusive rights to market a single-tablet HIV treatment containing JTK303 (elvitegravir) in Japan.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Torii gets Japanese marketing rights to HIV therapy from parent Japan Tobacco
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice